Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosoritide Phase 3 in Children With Achondroplasia
NCT03197766Phase 3Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- Dec 2016
- Primary completion
- Oct 2019
- Modality
- Peptides
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in achondroplasia (ACH) comparing Active BMN 111 with Placebo (2 arms). Primary endpoint: Annualized Growth Velocity at 52 weeks. Started Dec 2016; status: completed.
02
Drugs
vosoritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT03197766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03197766.